A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

Camryn was diagnosed with a low-grade glioma at age two after her parents noticed a lazy eye. Sixteen years, 11 brain surgeries and over six years of chemotherapy treatment, Camryn is now ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

Improving Oncotype DX turnaround time for timeliness of adjuvant therapy: A single-system, multi-site quality improvement study in early-stage HR-positive breast cancer. This is an ASCO Meeting ...

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...

Brain tumors have long forced pathologists into a difficult balancing act. Under the microscope, many look alike at first ...

Thousands of women diagnosed with high-risk, estrogen-receptor-positive breast cancer may no longer need chemotherapy, according to results from the OPTIMA trial set for presentation at the 2026 ...

A drug called selpercatinib cut the risk of early-stage lung cancer coming back by 83% in patients who carry a specific gene.